159 related articles for article (PubMed ID: 24812057)
1. Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts.
Neschadim A; Pritzker LB; Pritzker KP; Branch DR; Summerlee AJ; Trachtenberg J; Silvertown JD
Endocr Relat Cancer; 2014 Jun; 21(3):459-71. PubMed ID: 24812057
[TBL] [Abstract][Full Text] [Related]
2. Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.
Landriscina M; Bagalà C; Piscazzi A; Schinzari G; Quirino M; Fabiano A; Bianchetti S; Cassano A; Sica G; Barone C
Prostate; 2009 May; 69(7):744-54. PubMed ID: 19152342
[TBL] [Abstract][Full Text] [Related]
3. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
Hadaschik BA; Ettinger S; Sowery RD; Zoubeidi A; Andersen RJ; Roberge M; Gleave ME
Int J Cancer; 2008 May; 122(10):2368-76. PubMed ID: 18240145
[TBL] [Abstract][Full Text] [Related]
4. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
Gravina GL; Marampon F; Di Staso M; Bonfili P; Vitturini A; Jannini EA; Pestell RG; Tombolini V; Festuccia C
Prostate; 2010 Aug; 70(11):1166-78. PubMed ID: 20333699
[TBL] [Abstract][Full Text] [Related]
5. Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1.
Choi ES; Shim JH; Jung JY; Kim HJ; Choi KH; Shin JA; Nam JS; Cho NP; Cho SD
Cancer Sci; 2011 Apr; 102(4):742-8. PubMed ID: 21241418
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
Chiu FL; Lin JK
Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
[TBL] [Abstract][Full Text] [Related]
7. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
8. Novel oligomeric proanthocyanidin derivatives interact with membrane androgen sites and induce regression of hormone-independent prostate cancer.
Kampa M; Theodoropoulou K; Mavromati F; Pelekanou V; Notas G; Lagoudaki ED; Nifli AP; Morel-Salmi C; Stathopoulos EN; Vercauteren J; Castanas E
J Pharmacol Exp Ther; 2011 Apr; 337(1):24-32. PubMed ID: 21205921
[TBL] [Abstract][Full Text] [Related]
9. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts.
Chen D; Cui QC; Yang H; Barrea RA; Sarkar FH; Sheng S; Yan B; Reddy GP; Dou QP
Cancer Res; 2007 Feb; 67(4):1636-44. PubMed ID: 17308104
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model.
Sakai I; Miyake H; Terakawa T; Fujisawa M
Cancer Sci; 2011 Apr; 102(4):769-75. PubMed ID: 21214673
[TBL] [Abstract][Full Text] [Related]
11. A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions.
Maruyama-Takahashi K; Shimada N; Imada T; Maekawa-Tokuda Y; Ishii T; Ouchi J; Kusaka H; Miyaji H; Akinaga S; Tanaka A; Shitara K
Prostate; 2008 May; 68(6):640-50. PubMed ID: 18213631
[TBL] [Abstract][Full Text] [Related]
12. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
Festuccia C; Gravina GL; D'Alessandro AM; Muzi P; Millimaggi D; Dolo V; Ricevuto E; Vicentini C; Bologna M
Endocr Relat Cancer; 2009 Jun; 16(2):401-13. PubMed ID: 19153211
[TBL] [Abstract][Full Text] [Related]
13. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF
J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
[TBL] [Abstract][Full Text] [Related]
14. Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
Liu G; Taylor SA; Marrinan CH; Hsieh Y; Bishop WR; Kirschmeier P; Long BJ
Int J Cancer; 2009 Dec; 125(11):2711-20. PubMed ID: 19530253
[TBL] [Abstract][Full Text] [Related]
15. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
16. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.
Fizazi K; Sikes CR; Kim J; Yang J; Martinez LA; Olive MC; Logothetis CJ; Navone NM
Anticancer Res; 2004; 24(5A):2897-903. PubMed ID: 15517894
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
[TBL] [Abstract][Full Text] [Related]
18. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells.
Srinivasan S; Ranga RS; Burikhanov R; Han SS; Chendil D
Cancer Res; 2007 Jan; 67(1):246-53. PubMed ID: 17185378
[TBL] [Abstract][Full Text] [Related]
19. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
Sirotnak FM; She Y; Lee F; Chen J; Scher HI
Clin Cancer Res; 2002 Dec; 8(12):3870-6. PubMed ID: 12473602
[TBL] [Abstract][Full Text] [Related]
20. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
